874791-10-3 Usage
Uses
Used in Pharmaceutical Research and Development:
3,5-DIFLUOROTHIOBENZAMIDE serves as a valuable building block for the synthesis of pharmaceuticals and other fine chemicals. Its unique structure, which includes fluorine substitution and a thioamide group, provides a versatile template for the development of new drug candidates.
Used in Chemical Research:
In the field of chemical research, 3,5-DIFLUOROTHIOBENZAMIDE is employed to explore its reactivity, stability, and potential interactions with other molecules. This can lead to advancements in understanding chemical reactions and mechanisms, as well as the discovery of new compounds with specific properties.
Used in Biological Research:
3,5-DIFLUOROTHIOBENZAMIDE is also utilized in biological research to investigate its interactions with biological systems. This can include studies on its potential biological activity, such as enzyme inhibition or modulation of cellular processes, which may contribute to the development of new therapeutic agents or probes for biological investigations.
Check Digit Verification of cas no
The CAS Registry Mumber 874791-10-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,7,4,7,9 and 1 respectively; the second part has 2 digits, 1 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 874791-10:
(8*8)+(7*7)+(6*4)+(5*7)+(4*9)+(3*1)+(2*1)+(1*0)=213
213 % 10 = 3
So 874791-10-3 is a valid CAS Registry Number.
InChI:InChI=1/C7H5F2NS/c8-5-1-4(7(10)11)2-6(9)3-5/h1-3H,(H2,10,11)
874791-10-3Relevant academic research and scientific papers
Development of new deoxycytidine kinase inhibitors and noninvasive in vivo evaluation using positron emission tomography
Murphy, Jennifer M.,Armijo, Amanda L.,Nomme, Julian,Lee, Chi Hang,Smith, Quentin A.,Li, Zheng,Campbell, Dean O.,Liao, Hsiang-I.,Nathanson, David A.,Austin, Wayne R.,Lee, Jason T.,Darvish, Ryan,Wei, Liu,Wang, Jue,Su, Ying,Damoiseaux, Robert,Sadeghi, Saman,Phelps, Michael E.,Herschman, Harvey R.,Czernin, Johannes,Alexandrova, Anastassia N.,Jung, Michael E.,Lavie, Arnon,Radu, Caius G.
supporting information, p. 6696 - 6708 (2013/10/01)
Combined inhibition of ribonucleotide reductase and deoxycytidine kinase (dCK) in multiple cancer cell lines depletes deoxycytidine triphosphate pools leading to DNA replication stress, cell cycle arrest, and apoptosis. Evidence implicating dCK in cancer cell proliferation and survival stimulated our interest in developing small molecule dCK inhibitors. Following a high throughput screen of a diverse chemical library, a structure-activity relationship study was carried out. Positron Emission Tomography (PET) using 18F-L-1-(2′-deoxy-2′-FluoroArabinofuranosyl) Cytosine (18F-L-FAC), a dCK-specific substrate, was used to rapidly rank lead compounds based on their ability to inhibit dCK activity in vivo. Evaluation of a subset of the most potent compounds in cell culture (IC50 = ～1-12 nM) using the 18F-L-FAC PET pharmacodynamic assay identified compounds demonstrating superior in vivo efficacy.
